Original ArticleAnti–Vascular Endothelial Growth Factor Therapy for Diabetic Retinopathy: Consequences of Inadvertent Treatment Interruptions
Section snippets
Methods
This is a retrospective, multicenter, case series of patients treated exclusively with anti-VEGF therapy for PDR or nonproliferative diabetic retinopathy (NPDR), with or without diabetic macular edema (DME), and who were temporarily lost to follow-up. Patients were identified between April 10, 2017 and April 10, 2018 by recollection of the investigators. The institutional review board of the University of Michigan Medical School, Ann Arbor, Michigan waived oversight because the study involved
Results
Investigators at 6 centers identified 12 patients (13 eyes) that were treated solely with anti-VEGF therapy for DR and were subsequently lost to follow-up for a period of time. The average age of these patients was 56.6 ± 10.4 years and half were women (Table 1). All of the patients had type II diabetes mellitus, with a median disease duration of 19 years and a mean hemoglobin A1c of 9.5% ± 2.5%. Ten of the 13 eyes (77%) in this series were treated exclusively with anti-VEGF therapy for some
Discussion
This case series shows the potentially devastating visual consequences that may occur in a real-world setting when patients with DR are treated exclusively with anti-VEGF therapy and have an unanticipated interruption in treatment. Anti-VEGF therapy has proven to be noninferior to PRP in the treatment of PDR and has shown potential benefit for preventing DR progression or even causing its regression in the tightly controlled setting of a clinical trial where patients follow-up regularly.3, 9, 10
References (27)
- et al.
Factors associated with worsening proliferative diabetic retinopathy in eyes treated with panretinal photocoagulation or ranibizumab
Ophthalmology
(2017) - et al.
Long-term stability and visual outcome after favorable initial response of proliferative diabetic retinopathy to panretinal photocoagulation
Ophthalmology
(1991) Treatment of proliferative diabetic retinopathy. Long-term results of argon laser photocoagulation
Ophthalmology
(1985)- et al.
Long-term visual outcome in proliferative diabetic retinopathy patients after panretinal photocoagulation
Jpn J Ophthalmol
(1999) - et al.
The long-term effects of laser photocoagulation treatment in patients with diabetic retinopathy: the early treatment diabetic retinopathy follow-up study
Ophthalmology
(2003) Fifteen-year argon laser and xenon photocoagulation results of Bascom Palmer Eye Institute’s patients participating in the diabetic retinopathy study
Ophthalmology
(1991)- et al.
Long-term effects of therapy with ranibizumab on diabetic retinopathy severity and baseline risk factors for worsening retinopathy
Ophthalmology
(2015) - et al.
Gaps in receipt of regular eye examinations among medicare beneficiaries diagnosed with diabetes or chronic eye diseases
Ophthalmology
(2014) - et al.
Loss to follow-up in patients with proliferative diabetic retinopathy after panretinal photocoagulation or intravitreal anti-VEGF injections
Ophthalmology
(2018) - et al.
Outcomes of eyes lost to follow-up with proliferative diabetic retinopathy that received panretinal photocoagulation vs intravitreal anti-vascular endothelial growth factor
Ophthalmology
(2019)
Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial
Lancet
Diabetes mellitus and infection: an evaluation of hospital utilization and management costs in the United States
J Diabetes Complicat
Rationale and application of the protocol S anti-vascular endothelial growth factor algorithm for proliferative diabetic retinopathy
Ophthalmology
Cited by (54)
Compassionomics: The Science and Practice of Caring
2024, American Journal of OphthalmologyA Caveat About Financial Incentives for Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Retinopathy
2022, American Journal of OphthalmologyCitation Excerpt :Prophylactic treatment of a large cohort of patients will undoubtedly increase the incidence of post-injection endophthalmitis, with its potential for severe and irreversible vision loss; 3 of 160 patients in Protocol W suffered this complication,3,25 which is a catastrophic consequence considering that eyes in this cohort had a median initial BCVA of 20/20. Given these risks associated with an anti-VEGF injection-only treatment strategy, an objective analysis of cost, benefit, and risk concludes that PRP should be the preferred first-line treatment for PDR in most patients.17,26,27 It is possible that data from the 4-year extension of Protocol W and PANORAMA could change the calculus of risk versus benefit.
Outcomes of Eyes With Diabetic Macular Edema That Are Lost to Follow-up After Anti–Vascular Endothelial Growth Factor Therapy
2022, American Journal of OphthalmologyCitation Excerpt :Patients with more therapy break-offs had significantly greater declines in VA.10 In our study, a modest but significant decline in VA was observed after being LTFU with mean VA declining from about 20/50 at the visit before LTFU to about 20/70 at the first return visit. Significant declines in vision have also been found after anti-VEGF treatment breaks in PDR and nAMD.11,17-19 In contrast, a recent study by Yalamanchili and associates20 of 82 patients with DME who were LTFU for ≥3 months showed no significant difference in VA upon return to care when compared with matched control subjects who were not LTFU.
Intravitreal anti-vascular endothelial growth factor versus panretinal LASER photocoagulation for proliferative diabetic retinopathy: a systematic review and meta-analysis
2021, Canadian Journal of OphthalmologyCitation Excerpt :The treatment burden associated with anti-VEGF injections can be significant, and maintenance of efficacy requires ongoing assessment and intervention. Wubben et al. highlighted in a retrospective case series that patients with diabetes treated exclusively with anti-VEGF can have disruptions to treatment, which can in turn result in irreversible blindness through complications including neovascular glaucoma and tractional retinal detachment.37 The risk of vitreous hemorrhage, tractional retinal detachment, and permanent visual disability is well-known in patients with untreated PDR.2
Temporal Trends in the Treatment of Proliferative Diabetic Retinopathy: An AAO IRIS® Registry Analysis
2021, Ophthalmology Science
Supplemental Material available at AJO.com.